Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» U.S. Food and Drug Administration Approves Subcutaneous Formulation of ORENCIA® (abatacept), a Proven Non-Anti-TNF Biologic for Adults with Moderate to Severe Rheumatoid Arthritis
U.S. Food and Drug Administration Approves Subcutaneous Formulation of ORENCIA® (abatacept), a Proven Non-Anti-TNF Biologic for Adults with Moderate to Severe Rheumatoid Arthritis
U.S. Food and Drug Administration Approves Subcutaneous Formulation of ORENCIA® (abatacept), a Proven Non-Anti-TNF Biologic for Adults with Moderate to Severe Rheumatoid Arthritis
Submitted by
admin
on July 30, 2011 - 10:40am
Source:
Yahoo/BusinessWire
News Tags:
Orencia
rheumatoid arthritis
Bristol-Myers Squibb
Headline:
U.S. Food and Drug Administration Approves Subcutaneous Formulation of ORENCIA® (abatacept), a Proven Non-Anti-TNF Biologic for Adults with Moderate to Severe Rheumatoid Arthritis
Do Not Allow Advertisers to Use My Personal information
